About Inozyme Pharma
Inozyme Pharma is a company based in Cambridge (United States) founded in 2016 by Axel Bolte was acquired by BioMarin Pharmaceutical in May 2025. Inozyme Pharma has raised $116.4 million across 2 funding rounds from investors including BioMarin Pharmaceutical, TD Securities and RA Capital. The company has 59 employees as of December 31, 2023. Inozyme Pharma operates in a competitive market with competitors including Alnylam, Ultragenyx, BioMarin Pharmaceutical, Ardelyx and Mirum Pharmaceuticals, among others.
- Headquarter Cambridge, United States
- Employees 59 as on 31 Dec, 2023
- Founders Axel Bolte
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
$102.02 M (USD)43as on Dec 31, 2024
-
EBITDA
-$104.03 M (USD)-38as on Dec 31, 2024
-
Total Equity Funding
$116.4 M (USD)
in 2 rounds
-
Latest Funding Round
$67.4 M (USD), Series A
Apr 10, 2019
-
Investors
BioMarin Pharmaceutical
& 9 more
-
Employee Count
59
as on Dec 31, 2023
-
Acquired by
BioMarin Pharmaceutical
(May 16, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Inozyme Pharma
Unlock access to complete
Unlock access to complete
Funding Insights of Inozyme Pharma
Inozyme Pharma has successfully raised a total of $116.4M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $67.4 million completed in April 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Inozyme Pharma
Inozyme Pharma has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include BioMarin Pharmaceutical, TD Securities and RA Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biotech funding, drug development support, and investment in life sciences.
|
Locked | Locked | Locked | |
|
Early-stage and late-stage biotech and finance companies are funded.
|
Locked | Locked | Locked | |
|
Private equity firm focused on life science sector
|
Locked | Locked | Locked |
Investor details for Inozyme Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Inozyme Pharma
Investment portfolio details for Inozyme Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Inozyme Pharma
Detailed financials for Inozyme Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Inozyme Pharma Comparisons
Peer comparison for Inozyme Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Inozyme Pharma
Inozyme Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alnylam, Ultragenyx, BioMarin Pharmaceutical, Ardelyx and Mirum Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for rare genetic diseases are developed by BioMarin Pharmaceutical.
|
|
| Locked | Locked | Locked |
Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics are developed for rare diseases treatment.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for rare genetic diseases
|
Detailed competitors of Inozyme Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Inozyme Pharma
Complete news archive for Inozyme Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Inozyme Pharma
Inozyme Pharma was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Inozyme Pharma is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Axel Bolte is the current CEO of Inozyme Pharma. They have also founded this company.
Inozyme Pharma is a funded company, having raised a total of $116.4M across 2 funding rounds to date.
As of Dec 31, 2023, the latest employee count at Inozyme Pharma is 59.
Developer of treatments for rare and debilitating metabolic diseases. The companys product line include INZ-701, is an ENPP1 Fc fusion protein enzyme replacement therapy to increase PPi and adenosine, enabling the potential treatment of multiple diseases caused by deficiencies in metabolites.
Inozyme Pharma's top competitors include Alnylam, UniQure and BioMarin Pharmaceutical.
Inozyme Pharma has 10 investors. Key investors include BioMarin Pharmaceutical, TD Securities, RA Capital, Sofinnova, and Rock Springs Capital.